RDHL Stock Price, Chart, Stats & News

RedHill Biopharma Ltd.
Save
2.86M
Market cap
–
Current P/E
1428.57x
Forward P/E
RDHL chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | 64.45% |
Operating margin | -110.40% |
Pretax margin | -97.52% |
Net margin | -97.52% |
Effective tax rate | – |
ROA | -50.68% |
ROE | 204.79% |
D/E | -0.05x |
Interest coverage ratio | -10.30x |
RDHL valuation
P/E | – |
P/S | 0.26x |
P/B | -0.31x |
P/CF | -0.16x |
P/FCF | -0.30x |
P/OCF | -0.16x |
PEG | -0.00x |
EV multiple | -0.65x |
About
RedHill Biopharma Ltd. is a specialized pharmaceutical firm concentrating its efforts mainly on therapies for digestive tract conditions and various infections. The company markets several gastrointestinal medications: Movantik, which addresses opioid-induced constipation in adults experiencing chronic non-cancer pain; Talicia, used to treat Helicobacter pylori infections in adult patients; and Aemcolo, prescribed for adults suffering from travelers' diarrhea. Its robust late-stage clinical pipeline features several promising investigational compounds.
Similar securities
Based on sector and market capitalization
Report issue











